Sylvester Researchers Deliver Over 35 Oral Presentations at ASH 2025 Annual Meeting

Cutting-edge hematology research from the Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine is poised to make a profound impact at ASH 2025, the 67th annual meeting and exposition of the American Society of Hematology, scheduled for December 6-9 in Orlando, Florida. This prestigious event will showcase a wealth of pioneering findings that highlight groundbreaking therapeutic advances and novel diagnostic modalities targeting blood cancers and related disorders.

One of the standout presentations explores the synergistic potential of mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel, a chimeric antigen receptor T-cell (CAR-T) therapy, in refractory large B-cell lymphoma. Clinical data reveal remarkably high complete response rates at 90 days post-treatment, underscoring the promise of multi-agent immunotherapy protocols in overcoming tumor resistance mechanisms. This study elucidates intricate immune interactions and signaling cascades that bolster CAR-T cell functionality and persistence within the hostile tumor microenvironment.

Parallel research efforts delve into optimizing treatment paradigms for multiple myeloma, particularly focusing on abbreviated fixed-duration linvoseltamab immuno-consolidation for patients exhibiting minimal residual disease positivity post frontline therapy. This phase 2 trial investigates how targeted T-cell engagers can deepen disease remission rates, leveraging precise immunologic pathways to eradicate residual malignant plasma cells. The nuanced understanding of tumor immunology and minimal residual disease dynamics offers valuable insights into sustainable disease control.

In the realm of relapsed or refractory multiple myeloma, the Rekindle study evaluates a quadruplet therapeutic regimen comprising iberdomide, carfilzomib, daratumumab, and dexamethasone. This combination seeks to harness complementary mechanisms of action—immunomodulation, proteasome inhibition, monoclonal antibody targeting, and corticosteroid-induced cytotoxicity—to achieve robust clinical responses. Genomic and proteomic profiling of treated patients in this trial paves the way for personalized medicine strategies.

The clinical translation of a single-cell measurable residual disease (scMRD) assay marks another significant milestone, offering unprecedented resolution in detecting residual leukemic cells in acute myeloid leukemia (AML). This highly sensitive diagnostic tool enables real-world application, facilitating tailored therapy adjustments and early intervention. By dissecting leukemic heterogeneity at the single-cell level, this assay enhances prognostication and informs therapeutic decision-making.

Addressing adult T-cell leukemia-lymphoma, a phase 2 trial of AI-BEL—a novel regimen combining azidothymidine, interferon-alpha, and belinostat—has generated compelling safety and efficacy data. This combination harnesses antiviral activity and epigenetic modulation to disrupt malignant T-cell proliferation. The trial’s results provide valuable evidence for expanding therapeutic options for HTLV-1 associated hematologic malignancies.

Enzomenib, a menin-MLL inhibitor, emerges as a promising agent in acute leukemia therapeutic landscapes, particularly in combination with venetoclax and azacitidine for relapsed or refractory AML patients. Preliminary phase 1 data illustrate favorable pharmacokinetics and a manageable safety profile. The mechanistic basis of AT-rich interaction domain targeting positions enzomenib as a novel epigenetic modifier that effectively disrupts leukemogenic transcriptional programs.

Large-scale analyses from the NMDP-sponsored ACCESS study challenge the prevailing notion that donor-recipient HLA mismatches beyond a single locus compromise transplantation outcomes. This finding bears significant clinical implications for hematopoietic stem cell transplantation, potentially broadening the donor pool without sacrificing efficacy or safety, thereby benefiting many patients with limited donor availability.

Investigations into CAR-T cell therapy resistance have highlighted the role of neoantigen-driven epitope spreading and the genetic instability of tumor cells leading to HLA loss. These insights articulate complex tumor-immune dynamics governing treatment efficacy and resistance. Addressing these molecular obstacles may enhance strategies for durable remissions in large B-cell lymphoma.

Long-term follow-up from the S1826 study now confirms the superiority of nivolumab-AVD over brentuximab vedotin-AVD in advanced classical Hodgkin lymphoma, with a significant improvement in progression-free survival. This trial reinforces the utility of immune checkpoint inhibition in lymphoma management and encourages further exploration into checkpoint blockade combination treatments.

Innovative antibody-drug conjugates continue to evolve, exemplified by PF-08046044, a CD30-targeted therapy linked to a topoisomerase I inhibitor payload. Early phase 1 results report encouraging safety data alongside preliminary evidence of antitumor activity in relapsed or refractory lymphomas. These molecular constructs epitomize the integration of precise targeting and potent cytotoxic delivery.

Comprehensive genomic atlases, such as the MEASURE Genome Atlas detailing AML at diagnosis and complete remission, provide an invaluable resource for dissecting the molecular architecture of hematologic malignancies over the disease course. These efforts facilitate biomarker discovery and inform novel therapeutic target identification, pushing the envelope of precision oncology.

Emerging treatments in lower-risk myelodysplastic syndromes (LR-MDS) spotlight R289, a dual IRAK1/4 inhibitor, yielding promising phase 1b safety and efficacy outcomes. Targeting innate immune signaling modulation in MDS reflects an innovative approach toward mitigating ineffective hematopoiesis and disease progression. Concurrently, analyses from the Imerge trial emphasize correlations between treatment-induced cytopenias and clinical responses with imetelstat treatment, elucidating hematologic toxicity frameworks and therapeutic windows.

Collectively, the constellation of research presented by Sylvester and the University of Miami investigators at ASH 2025 underscores a transformative era in hematologic oncology, where molecular precision, immunologic finesse, and translational science converge. These advancements herald new standards of care, aiming to dramatically improve survival outcomes and quality of life for patients grappling with complex blood cancers.

News Publication Date: Not specified

Web References:
– https://umiamihealth.org/sylvester-comprehensive-cancer-center
– https://www.hematology.org/Meetings/Annual-Meeting